Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 2/3 2Phase 3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Solid Tumor 1

Interventions

pembrolizumab 28Cisplatin 24Oxaliplatin 22Irinotecan 22Fluorouracil 22Capecitabine 20Leucovorin 17Paclitaxel 16Cyclophosphamide 14Trastuzumab 12Nivolumab 11Carboplatin 11Gemcitabine 10Bevacizumab 10Docetaxel 9fludarabine 8aldesleukin 8S 1 (combination) 8Ramucirumab 7130-nm albumin-bound paclitaxel 7atezolizumab 6Albumin-Bound Paclitaxel 6Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Biopsy 5veliparib 4tislelizumab 4spartalizumab 4dehydroftorafur 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × disitamab vedotin × Clear all
NCT06078982 2023-10-12

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Shanghai East Hospital

Phase 1 Unknown
39 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡